Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
AssigneeBristol-Myers Squibb Company
InventorsMaria JURE-KUNKEL, David M. Berman, Alan J. Korman, Mark J. Selby, Suba Krishnan
Life of this patent
Estimating the term…
Abstract
This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to PD-1; and (b) an antibody or an antigen-binding portion thereof that specifically binds to CD137.
Claims20
A method for treating a subject afflicted with a cancer, comprising administering to the subject a combination of therapeutically effective amounts of:
- (a) a monoclonal antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor;
- and
- (b) a monoclonal antibody or an antigen-binding portion thereof that binds specifically to CD137.
The method of claim 12, wherein the anti-CD137 antibody is a chimeric, humanized or human monoclonal antibody or a portion thereof.
A kit for treating a subject afflicted with a cancer, comprising:
- (a) a dosage ranging from 0.1 to 10 mg/kg body weight of an anti-PD-1 antibody or an antigen-binding portion thereof;
- (b) a dosage ranging from 1 to 10 mg of an anti-CD137 antibody or an antigen-binding portion thereof;
- and
- (c) instructions for using the anti-PD-1 antibody and the anti-CD137 antibody in the method of any of claims 1-38.
Dependencies are inferred from the claim text.